Cel Sci (CVM) Enterprise Value (QoQ) (2010 - 2026)
Cel Sci (CVM) Enterprise Value (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.93 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.58 Bn | 78.59 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn |
| 4 | Moderna | 58.86 Bn | 53.73 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.42 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.19 Bn | 9.80 Bn | 668.28 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - |
| 10 | Cel Sci | 2.18 Mn | -4.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 69.79% |
| Dec 31, 2025 | 42.66% |
| Sep 30, 2025 | -508.80% |
| Jun 30, 2025 | 6.80% |
| Mar 31, 2025 | 58.20% |
| Dec 31, 2024 | 2.53% |
| Sep 30, 2024 | -988.09% |
| Jun 30, 2024 | 91.82% |
| Mar 31, 2024 | -63.48% |
| Dec 31, 2023 | 21.50% |
| Sep 30, 2023 | 19.18% |
| Jun 30, 2023 | 48.89% |
| Mar 31, 2023 | 44.24% |
| Dec 31, 2022 | 20.53% |
| Sep 30, 2022 | 19.24% |
| Jun 30, 2022 | 18.11% |
| Mar 31, 2022 | 7.62% |
| Dec 31, 2021 | 12.09% |
| Sep 30, 2021 | 10.40% |
| Jun 30, 2021 | -167.93% |